PubMed · 2020 · 20 citations · 14 references
Life SciencesImmunologyPharmacologyImmunopathologyInflammationInnate ImmunityAnkle ArthritisGoutInflammatory Cell ResponsesInflammatory MediatorsInflammatory SignalingSynovial InflammationAcute Gouty ArthritisAcute Inflammatory ResponseAnkle Synovial InflammationAnti-inflammatory TherapeuticsInflammatory Ankle ArthritisInflammatory Response GenesMyeloid Differentiation Primary Response 88 SignalingNuclear Factor Kappa B Modulation
OBJECTIVES: To investigate the anti-inflammatory effect of luteolin on the acute gouty arthritis (AGA) rats and the underlying mechanisms. METHODS: A total of sixty rats were chosen and randomly divided into 5 groups:A control group, a monosodium urate (MSU) group, a colchicine group, 2 luteolin groups (50 mg/kg, 150 mg/kg). The AGA model of rats was established by injecting monosodium urate (MSU) at the concentration of 25 mg/mL into the ankle joint cavity. Changes of joint swelling index at different time points and the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in serum and synovial were measured. The mRNA expression of TLR2, TLR4, and MyD88 in synovial tissue was detected by real-time PCR, and the protein expression of TLR2, TLR4, MyD88, and NF-κB in synovial tissues was determined by Western blotting. The inflammatory cells of the ankle joint and its surrounding soft tissues were observed after HE staining, and the expression of NF-κB was determined by immunohistochemistry. RESULTS: <0.01). CONCLUSIONS: Luteolin can reduce the inflammatory response of acute gouty arthritis via down-regulating the TLR/MyD88/NF-κB pathway, and it is expected to be an effective drug for the treatment of acute gouty arthritis.
14
Michael S. Hershfield, L. Jackson Roberts, Nancy J. Ganson et al. · Proceedings of the National Academy of Sciences · 2010 · 144 citations